Acambis shares soar on $548M buyout deal

Shares of Acambis soared after Sanofi Pasteur, the vaccine division of Sanofi-Aventis, announced that it planned to buy the vaccine developer for $548 million. Aside from the smallpox vaccine ACAM2000, which recently won a 10-year, $425 million contract from the U.S. government, Sanofi-Aventis also gains a slate of experimental vaccines for dengue fever, West Nile disease and clostridium difficile, influenza and genital herpes.

Sanofi Pasteur and Acambis are partnered on a variety of development programs already. And the deal underscores just how attractive vaccine companies have become. Sanofi-Aventis "quite liked what we had in Acambis," said Acambis Chief Executive Ian Garland.

- check out Sanofi's release
- read the Wall Street Journal report
- here's the AP story

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.